Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Influenza

Free Subscription 01.06.2026 3 Cell 1 Epidemiol Infect 1 J Immunol 3 J Infect 1 J Virol 1 J Virol Methods 1 PLoS Biol 1 PLoS Med 11 PLoS One 1 Proc Natl Acad Sci U S A 19 Vaccine 1 Virology 3 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Cell

1. DE SA KSG, Silva J, Bayarri-Olmos R, Baker CA, et al
   A causal link between autoantibodies and neurological symptoms in long COVID.
   Cell. 2026;189:3214-3235.
   PubMed         Abstract available
   
   
2. WALL EC, Richter AG
   Autoantibodies in long COVID: A mechanistic foothold in a heterogeneous disease.
   Cell. 2026;189:3179-3180.
   PubMed         Abstract available
   
   
3. FOURNIER M, Vanderkerken M, Dorgham K, Bastard P, et al
   Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.
   Cell. 2026;189:3236-3253.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

4. KITAMURA N, Kondo N, Ith S, Okuyama M, et al
   Post-pandemic immunity debt for paediatric infectious diseases in Japan between 2014 and 2024.
   Epidemiol Infect. 2026;154:e67.
   PubMed         Abstract available
   
   

   
   J Immunol

5. WANG Q, McManus LR, Levine KS, Blanc R, et al
   A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.
   J Immunol. 2026;215:vkag106.
   PubMed         Abstract available
   
   

   
   J Infect

6. WEE LE, Ho RWL, Lim JT, Lim SK, et al
   Real-world effectiveness of influenza vaccination amongst children aged under 5 in a tropical setting.
   J Infect. 2026 May 26:106771. doi: 10.1016/j.jinf.2026.106771.
   PubMed         Abstract available
   
   
7. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
   A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
   J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
   PubMed         Abstract available
   
   
8. KIM HK, Jo S, Min KD, Cho SI, et al
   Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in Patients With Cancer: Evidence From a Nationwide Target Trial Emulation.
   J Infect. 2026 Apr 28:106753. doi: 10.1016/j.jinf.2026.106753.
   PubMed         Abstract available
   
   

   
   J Virol

9. LOES AN, Tarabi RAL, Li SH, Atkinson RK, et al
   Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.
   J Virol. 2026 May 27:e0031726. doi: 10.1128/jvi.00317.
   PubMed         Abstract available
   
   

   
   J Virol Methods

10. ZENG Q, Liu L, Wang T, Zhang C, et al
    Artificial intelligence-assisted technology to reduce turnaround time for rapid diagnosis of infectious diseases.
    J Virol Methods. 2026;344:115392.
    PubMed         Abstract available
    
    

    
    PLoS Biol

11. ZHOU F, Periasamy S, Jackson ND, Cheng WS, et al
    Redundant and distinct mechanisms suppress innate immune activation during SARS-CoV-2 infection.
    PLoS Biol. 2026;24:e3003808.
    PubMed         Abstract available
    
    

    
    PLoS Med

12. JANSEN E, Bockstal V, Herschke F, Olsson Gisleskog P, et al
    Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.
    PLoS Med. 2026;23:e1004609.
    PubMed         Abstract available
    
    

    
    PLoS One

13. SILVA-VALENCIA J, Tu K, Moineddin R, Butt DA, et al
    Trends in pulmonary exercise testing utilization after the COVID-19 pandemic in Ontario: A population-cohort study.
    PLoS One. 2026;21:e0349020.
    PubMed         Abstract available
    
    
14. WARNE DJ, Varghese A, Brewster A, Browning AP, et al
    Bayesian uncertainty quantification to identify population level vaccine hesitancy behaviours.
    PLoS One. 2026;21:e0349499.
    PubMed         Abstract available
    
    
15. AKIN HY, Tuncali T, Gencer EB, Cengiz Seval G, et al
    Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.
    PLoS One. 2026;21:e0345137.
    PubMed         Abstract available
    
    
16. SIROTIAK Z, Oberhauser AM, Sirotiak AM, Nettleton KA, et al
    Exploring the perceived impact of physical activity on physical and mental health among individuals with long COVID: A qualitative interview inquiry.
    PLoS One. 2026;21:e0350121.
    PubMed         Abstract available
    
    
17. FIORE E, Taio G, Morandi N, Mazzotta E, et al
    Lung ultrasonography to assess efficacy of intranasal and parenteral vaccinations for bovine respiratory disease (BRD) in dairy calves.
    PLoS One. 2026;21:e0349953.
    PubMed         Abstract available
    
    
18. AGYEI G, El-Duah P, Dumevi RM, Muzeniek T, et al
    Serological responses to SARS-CoV-2 in urban and rural Ghana: Antibody waning and implications for long-term population immunity.
    PLoS One. 2026;21:e0348281.
    PubMed         Abstract available
    
    
19. ROSSI SL, Cheng DM, Sereda Y, Truong V, et al
    COVID-19 pandemic-related stress and substance use behaviors among people with HIV - a mixed method analysis.
    PLoS One. 2026;21:e0349567.
    PubMed         Abstract available
    
    
20. YEO HY, Park JY, Marsh S, Castelino L, et al
    Evidence mapping of preference elicitation for non-pharmaceutical interventions targeting respiratory viral transmission: A scoping review protocol.
    PLoS One. 2026;21:e0344828.
    PubMed         Abstract available
    
    
21. KUBILIUTE I, Zaboras E, Majauskaite F, Urboniene J, et al
    Predicting severe COVID-19 disease in adults: A single-centre cohort study during the first three pandemic waves in 2020-2021 in Vilnius, Lithuania.
    PLoS One. 2026;21:e0350112.
    PubMed         Abstract available
    
    
22. BRIDGMAN WH, Safta C, Ray J
    A scalable variational method for estimating the latent infection-rate field of an outbreak.
    PLoS One. 2026;21:e0350090.
    PubMed         Abstract available
    
    
23. STOTZER E, Graner S, Sengpiel V, Wessberg A, et al
    Crisis leadership and strategic decisions in Swedish maternity care during the COVID-19 pandemic: A deductive analysis from the COPE staff project.
    PLoS One. 2026;21:e0346625.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

24. ADIGA A, Chopra A, Wilson ML, Ravi SS, et al
    A high-resolution, US-scale digital similar of interacting livestock, wild birds, and human ecosystems for multihost epidemic spread.
    Proc Natl Acad Sci U S A. 2026;123:e2507074123.
    PubMed         Abstract available
    
    

    
    Vaccine

25. JUFUKU R, Shinchi H, Murata K, Chan M, et al
    TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.
    Vaccine. 2026;86:128762.
    PubMed         Abstract available
    
    
26. LIU R, Fan Y, Xiong S, Lin J, et al
    Drivers of and implementation strategies for influenza vaccination for cardiovascular populations in China: a scoping review.
    Vaccine. 2026;86:128761.
    PubMed         Abstract available
    
    
27. OKUBO Y, Honjyo R, Uda K, Miyairi I, et al
    Nationwide survey for household preparedness and vaccination acceptance during a novel influenza pandemic scenario in Japan, 2025.
    Vaccine. 2026;86:128738.
    PubMed         Abstract available
    
    
28. MYBURGH L, van Loon K, Koetsier J, Hansen Q, et al
    Conjugate vaccine technology enhances responses to influenza virus.
    Vaccine. 2026;86:128728.
    PubMed         Abstract available
    
    
29. HALFMANN PJ, Duffy A, Wang T, Kawaoka Y, et al
    Evaluating the immunogenicity of clade 2 and clade 3 sarbecovirus spike protein nanoparticle vaccines in Syrian hamsters.
    Vaccine. 2026;84:128653.
    PubMed         Abstract available
    
    
30. LAMBERT D, Luisi N
    Prevalence and correlates of COVID-19 vaccine uptake among sexual and gender minority adolescents in the southern United States.
    Vaccine. 2026;84:128661.
    PubMed         Abstract available
    
    
31. SHEN Y, Shahn Z, Robertson MM, Gebo K, et al
    Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort.
    Vaccine. 2026;84:128666.
    PubMed         Abstract available
    
    
32. MULLER MP, Soe P, Shulha HP, Isenor JE, et al
    mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network.
    Vaccine. 2026;84:128630.
    PubMed         Abstract available
    
    
33. AMOAKO N, Cohuet S, Adjei MR, Gurry C, et al
    COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.
    Vaccine. 2026 Feb 17:128310. doi: 10.1016/j.vaccine.2026.128310.
    PubMed         Abstract available
    
    
34. BALAM S, Kane F, Traore B, Konate D, et al
    Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
    Vaccine. 2025 Sep 1:127680. doi: 10.1016/j.vaccine.2025.127680.
    PubMed         Abstract available
    
    
35. GREY-JOHNSON M, Muhammad AK, Sillah F, Jones CJ, et al
    COVID-19 testing acceptance among symptomatic individuals screened for a randomized clinical trial in The Gambia.
    Vaccine. 2026;77 Suppl 1:127608.
    PubMed         Abstract available
    
    
36. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    PubMed         Abstract available
    
    
37. GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
    Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
    Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
    PubMed         Abstract available
    
    
38. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    PubMed         Abstract available
    
    
39. KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
    COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
    Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
    PubMed         Abstract available
    
    
40. ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
    Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
    Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
    PubMed         Abstract available
    
    
41. SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
    Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
    Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
    PubMed         Abstract available
    
    
42. CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
    Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
    Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
    PubMed         Abstract available
    
    
43. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    PubMed         Abstract available
    
    

    
    Virology

44. UNO N, Ross TM
    Intramuscular administration of influenza hemagglutinin in one hind leg elicits similar protective immune responses as administration in two hind legs.
    Virology. 2026;621:110961.
    PubMed         Abstract available
    
    

    
    Virus Res

45. FARSIU N, Mahani FK, Arefinia N, Charostad J, et al
    From Legacy to Innovation: A Comprehensive Review of Vaccine Platforms Against Viral Infections.
    Virus Res. 2026 Apr 16:199730. doi: 10.1016/j.virusres.2026.199730.
    PubMed         Abstract available
    
    
46. VAN DIJK LLA, Rijsbergen LC, Havelaar AC, den Hartog Y, et al
    Innate airway responses shape permissiveness to human respiratory syncytial virus.
    Virus Res. 2026;368:199734.
    PubMed         Abstract available
    
    
47. JANGJOU A, Izadpanah P, Moqhadas M, Faramarzi H, et al
    QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study.
    Virus Res. 2026;368:199739.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum